Please Share:: 
India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��
Result Review
Aventis Pharma – 4QCY2010
Aventis Pharma (Aventis) reported its 4QCY2010 results. Net sales for the quarter came in at
`287cr (`237cr), a yoy growth of 21% and higher than our estimate of `263cr. The domestic
markets contributed around 78% of the total revenues with the remaining coming from
exports. Gross margins increased to 50% (47%) yoy, though lower than our estimate of
54.5% on account of higher raw material costs. Consequently, OPM came in at 7.2% (6.9%),
below our estimate of 13.6%. Net profit before exceptional items increased by 12.3% to
`29.2cr (`26cr) yoy. Including the exceptional items amounting to `75.7cr on account of the
Chiron sale, net profit stood at `105cr (`26cr), up by a substantial 303.5%. The stock is
currently under review.
India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��
Result Review
Aventis Pharma – 4QCY2010
Aventis Pharma (Aventis) reported its 4QCY2010 results. Net sales for the quarter came in at
`287cr (`237cr), a yoy growth of 21% and higher than our estimate of `263cr. The domestic
markets contributed around 78% of the total revenues with the remaining coming from
exports. Gross margins increased to 50% (47%) yoy, though lower than our estimate of
54.5% on account of higher raw material costs. Consequently, OPM came in at 7.2% (6.9%),
below our estimate of 13.6%. Net profit before exceptional items increased by 12.3% to
`29.2cr (`26cr) yoy. Including the exceptional items amounting to `75.7cr on account of the
Chiron sale, net profit stood at `105cr (`26cr), up by a substantial 303.5%. The stock is
currently under review.
No comments:
Post a Comment